Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells

Blood

Volumn 103, Issue 8, 2004, Pages 3065-3072

  Verneris, Michael R ^a   Karami, Mobin ^b   Baker, Jeanette ^b   Jayaswal, Anlshka ^b   Negrin, Robert S ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CD8 ANTIGEN; IMMUNOGLOBULIN RECEPTOR; SMALL INTERFERING RNA; T LYMPHOCYTE RECEPTOR;

ANTIBODY SPECIFICITY; ARTICLE; CALCIUM TRANSPORT; CELL MEDIATED CYTOTOXICITY; CROSS LINKING; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EFFECTOR CELL; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOLECULAR RECOGNITION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; RECEPTOR UPREGULATION; T LYMPHOCYTE ACTIVATION; TARGET CELL;

EID: 1842526956     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-06-2125     Document Type: Article

References (46)

1. Lanier LL. NK cell receptors. Annu Rev Immunol. 1998;16:359-393.
2. Moretta L, Biassoni R, Bottino C, Mingari MC, Moretta A. Human NK-cell receptors. Immunol Today. 2000;21:420-422.
3. Houchins JP, Yabe T, McSherry C, Bach FH. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J Exp Med. 1991;173:1017-1020.
4. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity. 2002;17:19-29.
5. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol. 2000;1:119-126.
6. Cosman D, Mullberg J, Sutherland CL, et al. ULBPs, novel MHC class I-related molecules, bind to CMV grycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14:123-133.
7. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T, Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A. 1996;93:12445-12450.
8. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285:727-729.
9. Jan Chalupny N, Sutherland CL, Lawrence WA, Rein-Weston A, Cosman D. ULBP4 is a novel ligand for human NKG2D. Biochem Biophys Res Commun. 2003;305:129-135.
10. Radosavljevic M, Cuillerier B, Wilson MJ, et al. A cluster of ten novel MHC class I related genes on human chromosome 6q24.2-q25.3. Genomics. 2002;79:114-123.
11. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A. 1999;96:6879-6884.
12. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol. 2001;2:255-260.
13. Brooks CG, Urdal DL, Henney CS. Lymphokine-driven " differentiation" of cytotoxic T-cell clones into cells with NK-like specificity: correlations with display of membrane macromolecules. Immunol Rev. 1983;72:43-72.
14. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174:139-149.
15. + cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2001;7:216-222.
16. Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin R.S Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood. 1998;92:3318-3327.
17. Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol. 2002;116:78-86.
18. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 2001;97:2923-2931.
19. + NK T cells in the treatment of lymphoma. Biol Blood Marrow Transplant. 2001;7:532-542.
20. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000;356:802-807.
21. + T cells to Fas-mediated apoptosis. Cancer Immunol Immunother. 2000;49:335-345.
22. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol. 2000;1:119-126.
23. Pende D, Cantoni C, Rivera P, et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of non-epithelial origin. Eur J Immunol. 2001;31:1076-1086.
24. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994;153:1687-1696.
25. Schmidt-Wolf IG, Lefterova P, Mehta BA, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 1993;21:1673-1679.
26. Schmidt-Wolf IG, Aihara M, Negrin RS, Blume KG, Chao NJ. In vitro and in vivo activity of murine lymphokine-activated killer cells after cryopreservation. Transfusion. 1992;32:42-45.
27. Shimizu Y, Geraghty DE, Koller BH, Orr HT, De-Mars R. Transfer and expression of three cloned human non-HLA-A, B, C class I major histocompatibility complex genes in mutant lymphoblastoid cells. Proc Natl Acad Sci U S A. 1988;85:227-231.
28. Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat Immunol. 2003;4:557-564.
29. Drobyski WR, Majewski D, Ozker K, Hanson G. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment. J Immunol. 1998;161:2610-2619.
30. Leemhuis T, Wells S, Horn P, Sceffold C, Edinger M, Negrin RS. Autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma [abstract]. Blood. 2000;96:839a.
31. Kim JA, Bresler HS, Martin EW Jr, Aldrich W, Heffelfinger M, Triozzi PL. Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody. Cancer. 1999;86:22-30.
32. To WC, Wood BG, Krauss JC, et al. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg. 2000;126:1225-1231.
33. + natural killer T cells redirected with bispecific antibody F(ab′)(2)HER2xCD3. Cancer Res. 2002;62:5785-5791.
34. + killer cells. Blood. 1995;86:3493-3499.
35. Roberts AI, Lee L, Schwarz E, et al. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol. 2001;167::5527-5530.
36. Wu J, Groh V, Spies T. T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I-related chains by human epithelial gamma delta T cells. J Immunol. 2002;169:1236-1240.
37. Diefenbach A, Tomasello E, Lucas M, et al. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol. 2002;3:1142-1149.
38. Long EO. Versatile signaling through NKG2D. Nat Immunol. 2002;3:1119-1120.
39. Zompi S, Hamerman JA, Ogasawara K, et al. NKG2D triggers cytotoxicity in mouse NK cells lacking DAP12 or Syk family kinases. Nat Immunol. 2003;4:565-572.
40. + T-cell cultures. Scand J Immunol. 2002;56:602-610.
41. + T cells from human thymocytes by interleukin-15. J Interferon Cytokine Res. 2001;21:905-911.
42. Wu J, Song Y, Bakker AB, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science. 1999;285:730-732.
43. Salih RH, Antropius H, Gieske F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003;102:1389-1396.
44. Pende D, Rivera P, Marcenaro S, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002;62:6178-6186.
45. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A. 2001;98:11521-11526.
46. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001;413:165-171.